1990
DOI: 10.1007/bf01257078
|View full text |Cite
|
Sign up to set email alerts
|

Some central pharmacological effects of (+)- and (−)-oxaprotiline

Abstract: The central action of oxaprotiline (OXA) enantiomers, administered in a single dose, was studied in rats and mice. (+)-OXA and (-)-OXA attenuated reserpine- and apomorphine-induced hypothermia [(+)-OXA in a more potent manner] in mice and reduced the immobility time in the behavioural despair test in rats. Both OXA enantiomers inhibited locomotor activity in mice and rats, and enhanced and prolonged amphetamine- and apomorphine-induced stereotypy in rats. (-)-OXA potentiated the amphetamine hyperactivity in ra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1991
1991
2013
2013

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 16 publications
0
1
0
Order By: Relevance
“…An example of a nonmonoamine approach for the treatment of depression is based on modulation of the glutamatergic system, particularly via N-methyl-D-aspartate (NMDA) receptors. [5][6][7] A number of researchers have looked at the role of the glutamatergic system in depression and there is now evidence that this mood disorder is associated, at least partly, with increased levels of extracellular glutamate. 8 Clinical and preclinical studies increasingly support the glutamate-based hypothesis of depression by showing that ketamine, an NMDA receptor antagonist, elicits rapid antidepressant effects, [9][10][11] encouraging the assumption that modulation of glutamatergic neurotransmission might be a promising strategy for nextgeneration fast-acting antidepressants.…”
Section: Depressionmentioning
confidence: 99%
“…An example of a nonmonoamine approach for the treatment of depression is based on modulation of the glutamatergic system, particularly via N-methyl-D-aspartate (NMDA) receptors. [5][6][7] A number of researchers have looked at the role of the glutamatergic system in depression and there is now evidence that this mood disorder is associated, at least partly, with increased levels of extracellular glutamate. 8 Clinical and preclinical studies increasingly support the glutamate-based hypothesis of depression by showing that ketamine, an NMDA receptor antagonist, elicits rapid antidepressant effects, [9][10][11] encouraging the assumption that modulation of glutamatergic neurotransmission might be a promising strategy for nextgeneration fast-acting antidepressants.…”
Section: Depressionmentioning
confidence: 99%